Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity.

p38α mitogen-activated protein (MAP) kinase is a main target in drug research concerning inflammatory diseases. Nevertheless, no inhibitor of p38α MAP kinase has been introduced to the market. This might be attributed to the fact that there is no inhibitor which combines outstanding activity in biological systems and selectivity. Herein an approach to the development of such inhibitors on the basis of the highly selective molecular probe Skepinone-L is described. Introduction of a "deep pocket" moiety addressing the DFG motif led to an increased activity of the compounds. Hydrophilic moieties, addressing the solvent-exposed area adjacent to hydrophilic region II, conserved a high activity of the compounds in a whole blood assay. Combined with their outstanding selectivity and low ATP competitiveness, these inhibitors are very interesting candidates for use in biological systems and in therapy.

[1]  K. Kish,et al.  Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase. , 2008, Acta Crystallographica Section D: Biological Crystallography.

[2]  P. Dougherty,et al.  A p38 Mitogen-Activated Protein Kinase-Dependent Mechanism of Disinhibition in Spinal Synaptic Transmission Induced by Tumor Necrosis Factor-α , 2010, The Journal of Neuroscience.

[3]  J. A. Hirsch,et al.  Substituent effects on hydrogenation of aromatic rings: hydrogenation vs. hydrogenolysis in cyclic analogs of benzyl ethers , 1985 .

[4]  S. Laufer,et al.  p38α mitogen-activated protein kinase inhibitors, a patent review (2005 – 2011) , 2011, Expert opinion on therapeutic patents.

[5]  Daniel Rauh,et al.  Proteus in the World of Proteins: Conformational Changes in Protein Kinases , 2010, Archiv der Pharmazie.

[6]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.

[7]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[8]  Daniel Rauh,et al.  Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. , 2009, Journal of the American Chemical Society.

[9]  Wolfgang Albrecht,et al.  Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. , 2012, Nature chemical biology.

[10]  Tobias Gabriel,et al.  Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. , 2005, Current topics in medicinal chemistry.

[11]  Daniel Rauh,et al.  High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha. , 2009, Journal of the American Chemical Society.

[12]  T. Cheng,et al.  Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[13]  S. Laufer,et al.  Targeting the hinge glycine flip and the activation loop: novel approach to potent p38α inhibitors. , 2012, Journal of medicinal chemistry.

[14]  Daniel Rauh,et al.  A new screening assay for allosteric inhibitors of cSrc. , 2009, Nature chemical biology.

[15]  D. Zaller,et al.  Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. , 2003 .

[16]  Matthew R. Lee,et al.  MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38α Protein , 2005 .

[17]  S. Laufer,et al.  An immunosorbent, nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid-phase assays. , 2005, Analytical biochemistry.

[18]  D. Zaller,et al.  Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity , 2003, Nature Structural Biology.

[19]  D. Schollmeyer,et al.  Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase. , 2012, Journal of medicinal chemistry.

[20]  K. Dabbagh,et al.  Pamapimod, a Novel p38 Mitogen-Activated Protein Kinase Inhibitor: Preclinical Analysis of Efficacy and Selectivity , 2008, Journal of Pharmacology and Experimental Therapeutics.

[21]  Paul Bamborough,et al.  Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. , 2008, Bioorganic & medicinal chemistry letters.

[22]  Gerald T Miwa,et al.  Bioactivation of drugs: risk and drug design. , 2011, Annual review of pharmacology and toxicology.

[23]  J. Madwed,et al.  Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796). , 2003, Journal of medicinal chemistry.